Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Gross Margin (2016 - 2025)

Historic Gross Margin for Vanda Pharmaceuticals (VNDA) over the last 13 years, with Q3 2025 value amounting to 94.75%.

  • Vanda Pharmaceuticals' Gross Margin rose 1000.0% to 94.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.44%, marking a year-over-year increase of 8200.0%. This contributed to the annual value of 94.31% for FY2024, which is 19900.0% up from last year.
  • Vanda Pharmaceuticals' Gross Margin amounted to 94.75% in Q3 2025, which was up 1000.0% from 94.8% recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Gross Margin peaked at 95.13% during Q4 2024, and registered a low of 90.3% during Q3 2021.
  • In the last 5 years, Vanda Pharmaceuticals' Gross Margin had a median value of 92.36% in 2023 and averaged 92.24%.
  • In the last 5 years, Vanda Pharmaceuticals' Gross Margin crashed by -6400bps in 2021 and then skyrocketed by 27700bps in 2024.
  • Vanda Pharmaceuticals' Gross Margin (Quarter) stood at 90.83% in 2021, then dropped by -1bps to 90.33% in 2022, then increased by 2bps to 92.36% in 2023, then rose by 3bps to 95.13% in 2024, then fell by 0bps to 94.75% in 2025.
  • Its Gross Margin stands at 94.75% for Q3 2025, versus 94.8% for Q2 2025 and 92.96% for Q1 2025.